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Abstract 
Vascular calcification, which is common in the elderly and in patients with atherosclerosis, 
diabetes and chronic renal disease, increases the risk of cardiovascular morbidity and 
mortality. It is a complex, active and highly regulated cellular process that resembles 
physiological bone formation. It has previously been established that pharmacological doses 
of glucocorticoids facilitate arterial calcification. However, the consequences for vascular 
calcification of endogenous glucocorticoid elevation have yet to be established. 
Glucocorticoids (cortisol, corticosterone) are released from the adrenal gland, but can also be 
generated within cells from 11-keto metabolites of glucocorticoids (cortisone, 11-
dehydrocorticosterone [11-DHC]) by the enzyme, 11β-hydroxysteroid dehydrogenase type 1 
(11β-HSD1). In the current study we hypothesised that endogenous glucocorticoids facilitate 
vascular smooth muscle cell (VSMC) calcification and investigated the receptor-mediated 
mechanism underpinning this process. 
In vitro studies revealed increased phosphate-induced calcification in mouse VSMCs 
following treatment for 7 days with corticosterone (100 nM; 7.98 fold; P<0.01), 11-DHC 
(100 nM; 7.14 fold; P<0.05) and dexamethasone (10 nM; 7.16 fold; P<0.05), a synthetic 
glucocorticoid used as a positive control. Inhibition of 11β-HSD isoenzymes by 10 µM 
carbenoxolone reduced the calcification induced by 11-DHC (0.37 fold compared to 
treatment with 11-DHC alone; P<0.05). The glucocorticoid receptor (GR) antagonist 
mifepristone (10 µM) had no effect on VSMC calcification in response to corticosterone or 
11-DHC. In contrast, the mineralocorticoid receptor (MR) antagonist eplerenone (10 µM) 
significantly decreased corticosterone- (0.81 fold compared to treatment with corticosterone 
alone; P<0.01) and 11-DHC- (0.64 fold compared to treatment with 11-DHC alone; P<0.01) 
driven VSMC calcification, suggesting this glucocorticoid effect is MR-driven and not GR-
driven. Neither corticosterone nor 11-DHC altered the mRNA levels of the osteogenic 
markers PiT-1, Osx and Bmp2. However, DAPI staining of pyknotic nuclei and flow 
cytometry analysis of surface Annexin V expression showed that corticosterone induced 
apoptosis in VSMCs. 
This study suggests that in mouse VSMCs, corticosterone acts through the MR to induce pro-
calcification effects, and identifies 11β-HSD-inhibition as a novel potential treatment for 
vascular calcification. 
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Introduction 
 
Vascular calcification is a marker of increased cardiovascular disease risk in ageing, 
including in diabetes, atherosclerosis and chronic kidney disease (CKD) (Mackenzie and 
MacRae, 2011; Zhu et al., 2012). The etiology of mineral accumulation within the 
vasculature shares many similarities with that of bone formation. Indeed, several studies have 
reported that vascular smooth muscle cells (VSMCs), the predominant cell type involved in 
vascular calcification, can undergo phenotypic transition to osteoblastic, chondrocytic and 
osteocytic cells in a calcified environment (Johnson et al., 2005; Zhu et al., 2011). 
Furthermore, phosphate accelerates this trans-differentiation process, with the loss of 
characteristic smooth muscle markers and the increased expression of osteoblastic markers 
(eg. Osterix, PiT-1 and BMP2) (Montes de Oca et al., 2014; Nakagawa et al., 2010; Zhu et 
al., 2013). Vascular calcification can also proceed through mechanisms involving the 
reciprocal loss of recognised calcification inhibitors including inorganic pyrophosphate (PPi), 
fetuin A and Matrix Gla Protein (Johnson et al., 2005; Mackenzie et al., 2012; Murshed et al., 
2005; Reynolds et al., 2005). 
 
Physiological glucocorticoids - primarily cortisol in humans and corticosterone in rats and 
mice - are steroid hormones produced by the adrenal cortex. Local glucocorticoid action on 
target tissues is determined by intracellular metabolism by the two isozymes of 11β-
hydroxysteroid dehydrogenase (11β-HSD) which catalyze interconversion of active cortisol 
and corticosterone with inert cortisone and 11-dehydrocorticosterone (Hadoke et al., 2013). 
11β-HSD type 1, a predominant reductase in most intact cells, catalyzes the regeneration of 
active glucocorticoids, thus amplifying cellular action. 11β-HSD2 is a high-affinity 
dehydrogenase that inactivates glucocorticoids (Chapman et al., 2013). Both isozymes of 
11HSD are modestly expressed in the blood vessel wall, suggesting that they can influence 
vascular function by regulating local availability of active glucocorticoids (Hadoke et al., 
2013). 
 
In the absence of 11β-HSD2, endogenous glucocorticoids can bind to the mineralocorticoid 
receptor (MR) as well as the glucocorticoid receptor (GR) (Richardson et al., 2015). Both 
MR and GR belong to the same nuclear hormone receptor superfamily, and share high 
sequence identity. MR has higher affinity for glucocorticoids than GR, and both receptors are 
expressed in the cells of the vasculature (Hadoke et al., 2006). Glucocorticoids can activate 
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the MR in VSMCs (11β-HSD2 is not expressed here), inducing pathways that are central to 
cell proliferation and differentiation (Molnar et al., 2008). 
 
Glucocorticoids are frequently permissive, co-operative or synergistic (Wada, 2008). Indeed 
a permissive role of glucocorticoids in triggering cell transdifferentiation has previously been 
established in the conversion of pancreatic cells into hepatocytes (Shen et al., 2000). 
Furthermore, glucocorticoids exert complex actions on calcium mobilisation and bone 
metabolism, regulating bone resorption and formation (Hartmann et al., 2016), intestinal 
calcium absorption and renal calcium excretion (Diaz de Barboza et al., 2015).  Therefore it 
is essential to establish the consequences for vascular calcification of endogenous 
glucocorticoid elevation given the high circulating calcium levels commonly observed in 
patients with this pathology (Block, 2000).   
 
Dexamethasone, a potent synthetic glucocorticoid which is primarily active at the GR, 
induces an osteoblastic differentiation pathway in many different mesenchymal-derived cell 
types in vitro (Bellows et al., 1990; Cheng et al., 1994; Walsh et al., 2001), including VSMCs 
(Mori et al., 1999; Shui & Scutt, 2002). Whilst the established pro-calcification actions of 
dexamethasone on VSMCs (Kirton et al., 2006; Mori et al., 1999) are presumed to be 
mediated via GR, plausibly endogenous corticosteroids may modulate VSMC calcification 
via MR. This is therapeutically important to ascertain, as vascular calcification is 
independently correlated with adverse cardiac events (Zhu et al., 2012), and MR antagonism 
is highly successful in reducing mortality in heart failure (Vizzardi et al., 2014); aldosterone 
antagonists such as spironolactone and eplerenone have been shown to improve 
cardiovascular outcomes and prevent ischaemic events in cardiovascular patients (Pitt et al., 
1999; 2003). Corticosterone has been shown to induce rapid MR signalling in VSMCs that 
involves mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase 
(ERK)-dependent pathways, suggesting that glucocorticoids may contribute to vascular 
disease via MR receptor signalling (Molnar et al., 2008). Recent studies have shown that 
aldosterone-induced activation of MR promotes osteoblastic differentiation and calcification 
of VSMCs (Jaffe et al., 2007) through a mechanism involving the stimulation of 
spironolactone-sensitive, PiT-1 dependent signalling (Voelkl et al., 2013).  
 
An additional level of control over endogenous corticosteroid action is provided by the HSD 
isoenzymes, whose role in vascular calcification has yet to be elucidated. The induction of 
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local glucocorticoid generation through increased 11β-HSD1 expression (>10 fold) and 
activity (>4 fold) by inflammatory cytokines and glucocorticoids is well documented in 
fibroblasts and osteoblasts (Kaur et al., 2010; Sun & Myatt, 2003), which both have the 
capacity to calcify (Staines et al., 2014; Boraldi et al., 2014).  
 
It is therefore essential to establish the consequences for vascular calcification of endogenous 
glucocorticoid elevation and potential strategies for inhibition of calcification. The aims of 
this study were to undertake in vitro murine VSMC calcification studies to investigate both 
the identity of the receptor and the role of the 11β-HSD isoenzymes in corticosterone-induced 
calcification. 
 
Materials and Methods 
 
Mice 
All animal experiments were performed under UK Home Office licensed approval in 
accordance with Directive 2010/63/EU of the European Parliament and were maintained in 
accordance with Home Office guidelines for the care and use of laboratory animals. C57BL/6 
mice were supplied by Charles River Laboratories (Harlow, Essex, UK).  
 
Preparation of VSMCs 
Mice were euthanized by cervical dislocation. Primary murine VSMCs were isolated as 
described (Mackenzie et al., 2011). Briefly, after removal of the adventitia, the aorta was 
opened to expose the endothelial layer under a dissection microscope. Tissues from eight 
animals were pooled and incubated with 1mg ml
-1
 trypsin (Invitrogen, Paisley, UK) for 10 
min in order to enable the removal of any remaining adventitia and endothelium through 
further dissection. Following overnight incubation at 37ºC in a humidified atmosphere of 
95% air/5% CO2 in “growth medium” (α-MEM supplemented with 10% Fetal Bovine Serum 
and 1% gentamicin, all from Invitrogen), tissues were digested with 425U/ml collagenase 
type II (Worthington Biochemical Corporation, Lakewood, USA) for 5 h. Cell suspensions 
were centrifuged at 2000 g for 5 min. The cell pellet was washed and resuspended in growth 
medium. Isolated VSMCs were passaged in growth medium twice in T25 tissue culture flasks 
(Greiner Bio-one, GmbH, Frickenhausen, Baden-Wurttemberg, Germany) coated with 
0.25μg/cm2 laminin (Sigma, Poole, UK) to promote maintenance of the contractile 
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differentiation state (Johnson et al., 2008). VSMCs were subsequently seeded at a density of 
1.5x10
4
/cm
2
 in 12-well plates. 
 
Induction of VSMC calcification 
In vitro calcification of VSMCs was induced by culturing cells in growth medium containing 
3 mM inorganic phosphate (a mixture of NaH2PO4 and Na2HPO4, pH 7.4, Sigma) for up to 
14 days, with a medium change every 3 days, as previously described (Zhu et al., 2015; 
2016). The effects of glucocorticoids in FBS were assessed through comparison of charcoal-
stripped and standard FBS (Life Technologies Ltd). Cells were treated with corticosterone (1-
100 nM) (Sigma), 11-DHC (1-100 nM) (Steraloids, Newport, USA), carbenoxolone (10 µM) 
(Sigma), dexamethasone (1-100 nM) (Sigma), mifepristone (10 µM) (Sigma) or eplerenone 
(10 µM) (Sigma). The in vitro levels of corticosterone and 11-DHC used in the present study 
reflect those found in vivo. Plasma corticosterone levels in mice range from 20 nM (nadir, 
morning) to ~150 nM (peak, evening) and stress levels are typically 200-250 nM. Basal 
levels of plasma 11-DHC in mice have been reported at 2-5nM and stress levels >30nM 
(Harris et al., 2001). 
 
Determination of VSMC calcification 
Calcium deposition was quantified by HCl leaching, as described previously (Zhu et al., 
2014). Briefly, cells were washed twice with phosphate buffered saline (PBS) and incubated 
with 0.6M HCl at room temperature for 24 h. Calcium content was determined 
colorometrically by a stable interaction with phenolsulphonethalein using a commercially 
available kit (Randox Laboratories Ltd., County Antrim, UK), corrected for total protein 
concentration (Bio-Rad Laboratories Ltd, Hemel Hempstead, UK), and presented as a fold 
change compared with control. Calcium deposition was also evaluated by alizarin red 
staining. Cells were washed twice with PBS, fixed in 4% paraformaldehyde for 5 min at 4°C, 
stained with 2% alizarin red (pH 4.2) for 5 min at room temperature and rinsed with distilled 
water. 
 
Analysis of gene expression 
VSMCs were treated with corticosterone (Sigma) or 11-DHC (Steraloids, Newport, USA), 
for 48 h in serum free α-MEM (Invitrogen). RNA was extracted using RNeasy total RNA 
(Qiagen Ltd, Crawley, West Sussex, UK), according to the manufacturer’s instructions. RNA 
was quantified and reverse transcribed as previously described (Mackenzie et al., 2014). 
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Levels of specific mRNAs were measured using the SYBR green detection method (Roche, 
East Sussex, UK) as previously reported (Staines et al., 2014). Primers were obtained from 
Qiagen (sequences not disclosed) for PiT-1 (NM_001159593), Bmp2 (NM_007553) and 
Msx2 (NM_013601). 
 
Quantification of apoptosis 
On reaching confluence, cells were serum starved for 24 h, then treated with 100 nM 
corticosterone for 48 h. Cells were harvested by trypsinization and re-suspended in 25 µl 1% 
trypan blue (diluted 50% in PBS). Live cells, which exclude trypan blue and dead cells 
(stained blue) were counted using a haemocytometer, and the results expressed as the 
percentage of cells that were dead. Apoptotic VSMCs were determined by manually counting 
pyknotic nuclei after staining with DAPI (Invitrogen) as previously described (Guicciardi et 
al., 2011). Additionally, cells in different stages of apoptosis were analysed by flow 
cytometry using the TACS Annexin-V-FITC apoptosis detection kit (R&D systems, 
Abingdon, UK), according to the manufacturer’s instructions. Non-apoptotic cells do not 
stain with either Annexin-V FITC or propidium iodide. Early apoptotic cells are stained with 
Annexin-V FITC but not propidium iodide (green fluorescence). Late apoptotic cells are 
stained with both Annexin-V FITC and propidium iodide (dual green and red fluorescence). 
Necrotic cells are only stained with propidium iodide (red fluorescence). 10,000 cell events 
were recorded on a BD FACS Calibur and data were analyzed with FlowJo 8.8.4 flow 
cytometry analysis software (Tree Star Inc., Ashland, Oregon, USA). 
 
Statistical analysis 
General Linear Model analysis and the Students t-test were used to assess the data. All data 
are expressed as the mean +/- S.E.M. Statistical analysis was performed using Minitab 16. 
P<0.05 was considered to be significant. 
 
Results 
 
Glucocorticoids facilitates VSMC calcification 
We initially examined the effects of physiological glucocorticoids on the calcification of 
VSMCs, with the synthetic glucocorticoid dexamethasone used as a positive control. Since 
arterial calcification is highly correlated with elevated serum Pi levels, VSMCs were cultured 
in growth medium containing high (3 mM) Pi as previously described (Zhu et al., 
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2015;2016).  Cells were treated with dexamethasone, corticosterone or 11-DHC (1-100 nM) 
for up to 7 days. Dexamethasone treatment significantly increased calcium deposition of 
VSMCs (17.16 fold, P<0.05, Fig. 1A).  Both corticosterone and 11-DHC significantly 
increased calcium deposition in VSMCs cultured with un-stripped FBS (1.51 fold, P<0.001 
and 1.72 fold respectively, P<0.001; Fig. 1B). Surprisingly, 11-DHC was more potent than 
corticosterone, with a significant effect at 10 nM, compared to 100 nM for corticosterone. 
Using FBS stripped of steroids markedly increased the magnitude of the effects of both 
corticosterone and 11-DHC on VSMC calcification (7.98 fold, P<0.01 and 7.14 fold, P<0.05 
respectively; Fig. 1C). The 11β-HSD inhibitor carbenoxolone notably reduced 11-DHC-
induced calcification of VSMCS (0.37 fold compared to treatment with 11-DHC alone, 
P<0.001, Fig. 1D), confirming the 11β-HSD isoenzymes as key regulators of intracellular 
glucocorticoid levels (Chapman et al., 2013). 
 
Corticosterone and 11-DHC facilitate VSMC calcification through the MR. 
In order to establish whether corticosterone acts via GR or MR to induce VSMC 
calcification, antagonists of both MR (eplerenone) and GR (mifepristone) were employed. 
Mifepristone (10 µM) itself potentiated VSMC calcification, but did not alter the response to 
corticosterone (Fig. 2A) or 11-DHC (Fig. 2B). However, eplerenone (10 µM) significantly 
attenuated the effect of corticosterone (0.81 fold compared to treatment with corticosterone 
alone; P<0.01) and 11-DHC- (0.64 fold compared to treatment with 11-DHC alone; P<0.01) 
on VSMC calcification.  
 
Corticosterone and 11-DHC induce VSMC apoptosis. 
Published data implicate the transdifferentiation of VSMCs to an osteoblast-like phenotype as 
a mechanism underlying the effects of dexamethasone upon vascular calcification (Mori et 
al., 1999). We therefore next tested whether the same is true for physiological 
glucocorticoids. Interestingly, neither corticosterone nor 11-DHC altered mRNA levels of 
key osteogenic markers: PiT-1 (Fig. 3A), Osx (Fig. 3B) and Bmp2 (Fig. 3C). Recent reports 
have highlighted apoptosis as essential for the initiation and progression of phosphate-
induced vascular calcification (Son et al., 2008). Therefore we undertook a detailed 
assessment of apoptosis following glucocorticoid treatment. Corticosterone treatment 
significantly reduced cell viability (2.07 fold; P<0.01; Fig. 4A), and conversely increased cell 
death (2.53 fold; P<0.05; Fig. 4B) and apoptosis (Fig. 4C-E) as determined by DAPI staining 
of pykrotic nuclei and FACS analysis of cells positively stained for Annexin V.  
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Discussion 
 
It is well established that glucocorticoids mediate changes in vascular growth, function and 
structure (Hadoke et al., 2006). Previous studies in VSMCs have reported the pro-
calcification effects of dexamethasone, a potent synthetic glucocorticoid. Here we 
demonstrate for the first time the facilitation of vascular calcification by both the active 
physiological glucocorticoid corticosterone and the inactive metabolite 11-DHC.  
 
Currently 11β-HSD inhibition is therapeutically employed in topical preparations for the 
management of mouth ulcers (Hirata et al.,2013). Furthermore, 11β-HSD-inhibition has been 
shown to correct insulin resistance in rodent models of CKD, a hallmark of this disease in 
patients being vascular calcification (Block et al., 2000). The in vitro experiments undertaken 
in this study therefore identify 11β-HSD inhibition as a plausible treatment for vascular 
calcification, and requires further interrogation in vivo.  
 
Whilst VSMC calcification is facilitated by GR selective dexamethasone (Fig. 1; Mori et al., 
1999), and macrophage-specific GR inactivation reduces vascular calcification in a mouse 
model of atherosclerosis (Preusch et al., 2008), the pro-calcification effects of corticosterone 
and 11-DHC do not appear to be mediated through GR signalling. Furthermore, whilst 
dexamethasone has been previously reported to accelerate the osteogenic differentiation of 
vascular pericytes (Kirton et al., 2006) and bovine VSMCs (Mori et al., 1999), in the present 
study Osterix, Bmp2 and PiT-1 expression were unaltered in VSMCs treated with 
corticosterone or 11DHC. Interestingly, these data contrast with a previous demonstration of 
up-regulated PiT-1 in response to MR signalling (Voelkl et al., 2013). This paradigm likely 
reflects different mechanisms underpinning the calcification permitted by synthetic and 
physiological glucocorticoids. Indeed, our studies suggest that the pro-calcification effects of 
corticosterone and 11-DHC are mediated directly through MR, corroborating previous work 
in VSMCs showing the activation of MR signalling by glucocorticoids (Molnar et al., 2008). 
Furthermore, our data complement previous work revealing that CVCs (calcifying vascular 
cells; subpopulations of VSMCs which have been found to spontaneously calcify in vitro) 
contain MRs which function as transcriptional regulators that can be activated by both 
aldosterone and cortisol (Jaffe et al., 2007). Indeed aldosterone administration has been 
shown to directly stimulate CVC calcification, an effect abolished by aldosterone antagonism 
with spironolactone (Jaffe et al., ATVB 2007). Moreover, vascular calcification facilitated by 
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hyperaldosteronism due to klotho deficiency has also been shown to be mitigated by 
spironolactone treatment in mice (Voelkl et al., 2013). Further studies are therefore required 
to directly compare the effects of aldosterone treatment on VSMC calcification with that of 
corticosterone and 11-DHC. 
 
The present study also highlights that the effect of corticosterone and 11-DHC on driving 
VSMC calcification is more pronounced when charcoal stripped media is used to remove 
endogenous steroid ligands, suggesting an activating effect of endogenous MR ligands in 
normal, unstripped serum. These data support comparable findings demonstrating that 
aldosterone-induced CVC calcification via MR activation is also enhanced using charcoal 
stripped serum (Jaffe et al., 2007). 
 
Mechanistically, our data reveal that corticosterone reduces cell viability and stimulates 
VSMC apoptosis. This process is essential for the initiation and progression of phosphate-
induced vascular calcification (Son et al., 2008), with apoptotic bodies exposing 
phosphatidylserine on the outer membranes, generating a potential calcium-binding site 
suitable for hydroxyapatite deposition (Proudfoot et al., 2000; Skrtic & Eanes, 1992). These 
results support previous reports demonstrating that glucocorticoids inhibit VSMC 
proliferation (Longenecker et al., 1984; Versaci et al., 2002) and induce apoptosis in a range 
of cell types including neuronal cells, growth plate chondrocytes and thymocytes 
(Chmielewski  et al., 2000; Chrysis et al., 2005; Liu  et al., 2011 and Li et al., 2014).  
 
In conclusion, we have undertaken in vitro murine VSMC studies to provide new insights 
into the role of physiological glucocorticoids in vascular calcification. Our study suggests 
that corticosterone acts through the MR to induce pro-calcification effects. This data may 
have important health ramifications for patients receiving MR blockers. The previously 
established clinical cardiovascular benefits of eplerenone administration (Pitt et al., 2003), in 
conjunction with our in vitro findings may pave the way for pre-clinical and clinical trials for 
the treatment of vascular calcification with eplerenone therapy. Inhibiting 11β-HSD 
isoenzymes and subsequently diminishing vascular calcification may also represent a novel 
potential pharmaceutical target for clinical intervention. 
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Figure legends 
 
Figure 1: Dexamethasone, corticosterone and 11-DHC all glucocorticoids induce VSMC 
calcification. Effect of (A) Dexamethasone (1-100nM) (B,C) Corticosterone (white bar) and 
11-dehydrocorticosterone (11DHC; filled bar) (1-100nM) in the presence of standard and 
charcoal-stripped Fetal Bovine Serum (FBS) respectively and (D) Carbenoxolone (10 µM) in 
the presence or absence of 11DHC (100 nM) on calcium deposition in VSMCs cultured in 
high phosphate (Pi) (3mM Pi) for 7 days, as determined by alizarin red staining and/or 
quantitative HCL leaching (μg/mg protein) (n=6). Results are presented as mean+/- S.E.M. 
*P<0.05; **P<0.01; ***P<0.001 compared with corresponding 0 nM treatment. 
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Figure 2: Endogenous glucocorticoids induce VSMC calcification through the 
Mineralocorticoid Receptor (MR). Effect of (A) Mifepristone (10µM) and (B) Eplerenone 
(10µM) in the presence of Corticosterone (100nM) and (C) Mifepristone (10µM) and (D) 
Eplerenone (10µM) in the presence of 11-dehydrocorticosterone (11HDC; 100nM)) on 
calcium deposition in VSMCs cultured in high phosphate (Pi) (3mM Pi) for 7 days, as 
determined by quantitative HCL leaching (μg/mg protein) (n=6). Results are presented as 
mean+/- S.E.M. *P<0.05; **P<0.01; ***P<0.001. 
 
Figure 3: Endogenous glucocorticoids do not induce osteogenic marker expression in 
VSMCs. Fold change in the mRNA expression of osteogenic markers (A) PiT-1 (B) Osx and 
(C) Bmp2 (n=4) following treatment with Corticosterone (white bar) and 11-
dehydrocorticosterone (11DHC; filled bar) (1-100nM). 0 nM treatment expressed as 1 to 
indicate fold change for each gene of interest. Results are presented as mean +/- S.E.M. 
*P<0.05; **P<0.01; ***P<0.001 compared with corresponding 0 nM treatment.  
 
Figure 4: Endogenous glucocorticoids induce apoptosis in VSMCs. Effect of 
Corticosterone (1-100nM) on (A) Alamar blue uptake (OD 570nm-620nm) (B) Trypan Blue 
uptake (%) (C) and (D) Apoptotic nuclei as determined by DAPI staining (%) and (E) 
Annexin V staining of isolated cells as assessed by FACs analysis. Results are presented as 
mean +/- S.E.M. *P<0.05; **P<0.01; ***P<0.001 compared with corresponding 0 nM 
treatment. 
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Fig. 4 
